

Supplementary information for:

“Direct Alkenyl C-H Functionalization of Cyclic Enamines with Carboxylic Acids via Rh Catalysis Assisted by Hydrogen Bonding”

Zhi-Quan Lei,[†] Jian-Heng Ye,[†] Jian Sun*,[†] and Zhang-Jie Shi*[‡],

[†]Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, Sichuan 610041

[‡]Beijing National Laboratory of Molecular Sciences (BNLMS) and Key Laboratory of
Bioorganic Chemistry and Molecular Engineering of the Ministry of Education, College of
Chemistry and Green Chemistry Center, Peking University, Beijing 100871

[‡]State Key Laboratory of Organometallic Chemistry, Chinese Academy of Sciences, Shanghai
200032, China.

Email: zshi@pku.edu.cn; sunjian@cib.ac.cn;

Table of Contents

General Experimental Section	S2
General Experimental Procedures	S3-S6
Characterization of Enamine Substrates 1 in Details	S7-S9
Characterization of Products in Details	S10-S23
NMR Spectra of Enamine Substrates 1	S24-S33
NMR Spectra of Products 2, 3 and 4	S34-S68
References	S69



General Experimental Section

Analytic methods.

^1H NMR, ^{13}C NMR data were obtained on Bruker 400 M nuclear resonance spectrometers unless otherwise specified, respectively. CDCl_3 as solvent and tetramethylsilane (TMS) as the internal standard were employed. Chemical shifts were reported in units (ppm) by assigning TMS resonance in the ^1H NMR spectrum as 0.00 ppm. The data of ^1H NMR was reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet and br = broad), coupling constant (J values) in Hz and integration. Chemical shifts for ^{13}C NMR spectra were recorded in ppm from TMS using the central peak of CDCl_3 (77.0 ppm) as the internal standard. Flash chromatography was performed using 200 - 300 mesh silica gel with the indicated solvent system according to standard techniques. Analytical thin - layer chromatography (TLC) was performed on pre-coated, glass-backed silica gel plates. Visualization of the developed chromatogram was performed by UV absorbance (254 nm). HRMS (ESI) analysis was performed by Analytical Instrumentation Center, Chengdu Institute of Biology, Chinese Academy of Sciences.

General preparation for chemicals.

Dicarbonylacetylacetonato rhodium(I) (99%), Chloro(1,5-cyclooctadiene)rhodium(I)(97%) dimer, Hydroxy(1,5-cyclooctadiene)rhodium(I)dimer,min.(97%), and Dicarbonylchlororhodium(I) dimer (97%) were purchased from Alfa Aesar. All the acids were purchased from Alfa Aesar. All the solvents were directly used from purchased without any further purification unless otherwise specified.

General Experimental Procedures

General procedure for preparation of enamine substrates 1

The substituted 2-aminepyridines were prepared as equations (S1-S3) below.

(Equation S1) 3-Hydroxy-4-pyridine (78.5 mmol, 7.46g) was added to ice cold H_2SO_4 (42 ml), concentrated HNO_3 (4 ml) was added dropwise while maintaining the temperature below $10\text{ }^\circ\text{C}$.^[1] After addition, the reaction was monitored by TLC until disappearance of the starting material in about 4 h. The ice cold water was added with caution and then it was neutralized to pH=6 by saturated potassium carbonate. It was cooled and then solid precipitated, it was filtered and washed with petroleum ether/EtOAc =10/1. Recrystallized in petroleum ether/EtOAc and afforded yellow solid. The aqueous phase was extracted by EtOAc and combined with the mother solution and purified by flash chromatography on silica gel with petroleum ether/EtOAc (5:1). The two parts were combined to give the desired product 8.25g.

2-Nitro-3-hydroxy-4-pyridine (20 mmol, 2.82g) and potassium carbonate (40 mmol, 5.52g) were half-dissolved in acetone (150 ml), Me_2SO ^[2] (26 mmol, 2.46 ml) or BnBr ^[3] (26 mmol, 3.09 ml) was added dropwise at $0\text{ }^\circ\text{C}$ and stirred at room temperature until disappearance of the starting material. It was quenched by water and the solvent was removed and extracted by EtOAc, dried over Na_2SO_4 , evaporated in vacuum to afford crude product which was purified by flash chromatography on silica gel with ether/EtOAc (10:1) to produce the desired product. And finally the methyl ether was reduced by Pd/C, H_2 and benzyl ether was reduced by Fe/AcOH.

(Equation S2) The newly prepared sodium methoxide (200 mmol, 10.8g) was mixed with 3,5-dichloropyridine (20 mmol, 2.96g) and dissolved in DMF (60 ml) in the atmosphere of N_2 , it was heated to $80\text{ }^\circ\text{C}$ for 36 h and then cooled to room temperature.^[4] The DMF was removed under reduced pressure and washed with water (20 ml), extracted by EtOAc, dried over Na_2SO_4 , evaporated in vacuum to afford product which was purified by flash chromatography on silica gel with petroleum ether/EtOAc (10:1) to produce the desired product 1.81g.

3,5-Dimethoxy-4-pyridine (10 mmol, 1.39g) was dissolved in concentrated H_2SO_4 (20 ml), HNO_3 (10.5 mmol, 0.675 ml) and H_2SO_4 (20 ml) were mixed and added dropwise at $0\text{ }^\circ\text{C}$.^[5] It was stirred for 5 minutes and quenched by ice and extracted by

EtOAc, dried over Na₂SO₄, evaporated in vacuum to afford crude product which was purified by flash chromatography on silica gel with petroleum ether/EtOAc (4:1) to produce the desired product 1.57 g. And finally it was reduction by Pd/C, H₂ in at room temperature.

(Equation S3) Br₂ (107.26 mmol, 5.50 ml) was added to 10% NaOH solution 50 ml 5-10 °C. This sodium hypobromide solution was added over 2 h to a solution of 3-hydropyridine (105.15 mmol, 10 g) in 10% NaOH (50 ml).^[6] The mixture was for additional 2 h. Acetic acid was added to bring the pH of the solution to between 6 and 7. The mixture was cooled to 5 °C for 1 h, and product was filtered off. It was washed with water and dried in vacuo at 85 °C to give the product 6.4 g as white solid. The methylation^[2, 7], nitration^[1, 8], debromide and reduction^[8] to afford the desired product.

Substrates **1a-1j** was prepared by condensation of 1,2-ketones with substituted arylamine or acetamide as equation below.^[9]

(Equation S4) In a 50 mL round bottom flask, equipped with a condenser, 1,2-dione (10 mmol), arylamine or acetic amide (10 mmol), alumina (10 g) and toluene (30 mL) was stirred and heated to reflux for 36 h. Upon reaction completion, alumina was removed by filtration and washed with EtOAc. The organic phases were combined and concentrated under vacuum and the residue was purified by flash chromatography eluting with petroleum ether/EtOAc (20:1-4:1) to give substrates **1a-1j**.

General Experimental Procedures and Characterizations

[Rh(cod)Cl]₂ (0.005 mmol, 2.4 mg) or [Rh(CO)₂Cl]₂ (0.005 mmol, 1.9 mg), enamine **1** (0.2 mmol), and carboxylic acid (0.24 mmol) were added to a Schlenk flask, which was then degassed with N₂ for three times. (tBuCO)₂O (0.3 mmol) and 2 mL of anhydrous toluene were added, and the reaction mixture was subsequently heated and kept at 140°C in oil bath for the indicated time with stirring. After cooling to room temperature, 1 mL of a concentrated ammonia solution was added. The mixture was directly subjected to column chromatograph on silica gel with petroleum ether/EtOAc (12:1-5:1) as eluent to afford the desired product **2** or **3**.

General Experimental Procedures for 1 mmol scale

[Rh(cod)Cl]₂ (0.025 mmol, 12 mg) enamine **1c** (1 mmol, 218.3 mg), and carboxylic acid (0.24 mmol) were added to a Schlenk flask, which was then degassed with N₂ for three times. (tBuCO)₂O (3 mmol, 0.305) and 10 mL of anhydrous toluene were added, and the reaction mixture was subsequently heated and kept at 140°C in oil bath for the indicated time with stirring. After cooling to room temperature, 4 mL of a concentrated ammonia solution was added. The mixture was directly subjected to column chromatograph on silica gel with petroleum ether/EtOAc (12:1-5:1) as eluent to afford the desired product **2** or **3**.

The hydrolysis of enamine product

(Equation S5) In a sealed tube, substrate **2a** (0.2 mmol, 58.8 mg), TsOH (0.8 mmol, 137.8 mg) and toluene/H₂O (1/1, 4 ml) were stirred at 140°C for 36 h. After reaction completed, the mixture was extracted with EtOAc (3 x 10 mL). The combined organic phase was washed with sat. NaHCO₃ (10 mL) and brine (10 mL) and dried over Na₂SO₄. The solvent was removed under vacuum and the residue was purified by flash chromatography eluting with petroleum ether/EtOAc (10:1) to give product **4a** (24.5 mg, 65%) as white solid, part of **2a** was recovered (14.7 mg, 25%).

(Equation S6) In a sealed tube, substrate **2w** (0.2 mmol), TsOH (0.8 mmol, 137.8 mg) and toluene/H₂O (1/1, 4 ml) were stirred at 140°C for 24 h. After reaction completed, the mixture was diluted with 10 mL water and extracted with EtOAc (3 x 10 mL). The combined organic phase was washed with sat. NaHCO₃ (30 mL) and brine (30 mL) and dried over Na₂SO₄. The solvent was removed under vacuum and the residue was purified by flash chromatography eluting with petroleum ether/EtOAc (10:1) to give product **4w** (21.0 mg, 75%) as pale oil.

Characterization of Enamine Substrates 1 in Details

5-methyl-2-(pyridin-2-ylamino)cyclopent-2-enone

Compound **1a**^[9] was obtained as amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.25 (dd, *J* = 5.2, 1.2 Hz, 1H), 7.67 (t, *J* = 3.2 Hz, 1H), 7.51 (ddd, *J* = 8.4, 7.2, 2.0 Hz, 1H), 6.78-6.75 (m, 2H), 6.70 (d, *J* = 8.4 Hz, 1H), 2.95 (ddd, *J* = 18.4, 6.4, 3.2 Hz, 1H), 2.50-2.42 (m, 1H), 2.27 (ddd, *J* = 18.4, 3.2, 2.0 Hz, 1H), 1.23 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.25, 154.33, 147.88, 137.33, 137.05, 131.27, 115.39, 110.63, 37.83, 33.86, 16.36.

5-methyl-2-((3-methylpyridin-2-yl)amino)cyclopent-2-enone

Compound **1b** was obtained as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, *J* = 4.0 Hz, 1H), 7.83 (t, *J* = 2.8 Hz, 1H), 7.34 (d, *J* = 6.8 Hz, 1H), 6.72 (dd, *J* = 7.2, 5.2 Hz, 1H), 6.66 (br, 1H), 2.96 (ddd, *J* = 18.0, 6.4, 3.2 Hz, 1H), 2.51-2.43 (m, 1H), 2.31-2.27 (m, 1H), 2.25 (s, 3H), 1.24 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.50, 152.77, 145.29, 137.53, 136.88, 132.09, 118.33, 115.40, 37.80, 33.93, 16.82, 16.40.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₅H₁₅N₂O: 203.1179; found 203.1181.

2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Compound **1c** was obtained as yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.85-7.82 (m, 2H), 7.34 (br, 1H), 6.95 (dd, *J* = 7.6, 1.2 Hz, 1H), 6.72 (dd, *J* = 8.0, 4.8 Hz, 1H), 3.87 (s, 3H), 2.94 (ddd, *J* = 18.4, 6.4, 3.2 Hz, 1H), 2.48-2.40 (m, 1H), 2.26 (ddd, *J* = 18.2, 3.2, 2.0 Hz, 1H), 1.23 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.27, 145.53, 142.95, 138.25, 136.75, 131.88, 114.73, 114.62, 55.26, 37.81, 33.90, 16.44.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₂H₁₅N₂O₂: 219.1128; found 219.1132.

2-((3-(benzyloxy)pyridin-2-yl)amino)-5-methylcyclopent-2-enone

Compound **1d** was obtained as yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.85-7.84 (m, 2H), 7.47 (br, 1H), 7.43-7.33 (m, 5H), 6.99 (d, $J=8.0$ Hz, 1H), 6.67 (dd, $J=7.6, 5.2$ Hz, 1H), 5.14 (s, 2H), 2.95 (ddd, $J=18.4, 6.4, 3.2$ Hz, 1H), 2.48-2.41 (m, 1H), 2.27 (d, $J=18.4$ Hz, 1H), 1.24 (d, $J=7.6$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.17, 145.74, 141.84, 138.63, 136.69, 135.89, 131.89, 128.67, 128.14, 127.03, 116.48, 114.65, 70.21, 37.78, 33.88, 16.36.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$: 295.1441; found 295.1447.

2-((3,5-dimethoxy)pyridin-2-yl)amino)-5-methylcyclopent-2-enone

Compound **1e** was obtained as yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.73-7.72 (m, 1H), 7.48 (s, 1H), 7.11 (br, 1H), 6.65 (s, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 2.94-2.87 (m, 1H), 2.43-2.38 (m, 1H), 2.23 (d, $J=18.0$ Hz, 1H), 1.20 (d, $J=7.2$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.31, 150.25, 143.54, 140.06, 136.94, 130.00, 120.82, 105.82, 56.18, 55.38, 37.80, 33.78, 16.41.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_3$: 249.1234; found 249.1237.

2-((5-methoxy)pyridin-2-yl)amino)-5-methylcyclopent-2-enone

Compound **1f** was obtained as yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, $J=2.8$ Hz, 1H), 7.54 (t, $J=3.2$ Hz, 1H), 7.17 (dd, $J=8.8, 2.8$ Hz, 1H), 6.68 (d, $J=8.8$ Hz, 1H), 6.62 (br, 1H), 3.81 (s, 3H), 2.93 (ddd, $J=18.0, 6.4, 3.2$ Hz, 1H), 2.49-2.41 (m, 1H), 2.26 (ddd, $J=18.4, 2.8, 2.0$ Hz, 1H), 1.23 (d, $J=7.6$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.34, 150.05, 148.71, 137.41, 132.81, 129.24, 125.17, 111.13, 56.10, 37.85, 33.73, 16.36.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_2$: 219.1128; found 219.1133.

N-(4-methyl-5-oxocyclopent-1-en-1-yl)acetamide

Compound **1g** was obtained as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.76-7.74 (m, 2H), 2.87 (ddd, $J=18.8, 6.0, 4.7\text{Hz}$, 1H), 2.40-2.32 (m, 1H), 2.23-2.17 (m, 1H), 2.12 (s, 3H), 1.15 (d, $J = 7.6\text{ Hz}$, 3H).

^{13}C NMR (100MHz, CDCl_3) δ 206.45, 168.80, 139.23, 135.67, 37.72, 34.03, 23.60, 15.99.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_8\text{H}_{12}\text{NO}_2$: 154.0863; found 154.0868.

2-((2-methoxyphenyl)amino)-5-methylcyclopent-2-enone

Compound **1h** was obtained as yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.21 (d, $J = 7.6\text{ Hz}$, 1H), 6.95- 6.90 (m, 1H), 6.87-6.86 (d, $J = 4.0\text{ Hz}$, 2H), 6.84 (br, 1H), 6.68 (t, $J = 3.2\text{ Hz}$, 1H), 3.88 (s, 3H), 2.91 (ddd, $J = 18.0, 6.4, 3.2\text{ Hz}$, 1H), 2.50-2.42 (m, 1H), 2.26-2.20 (m, 1H), 1.24 (d, $J = 7.6\text{ Hz}$, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.31, 147.96, 138.66, 131.52, 122.91, 120.69, 120.08, 114.17, 110.07, 55.49, 37.77, 33.30, 16.42.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{13}\text{H}_{16}\text{NO}_2$: 218.1176; found 218.1180.

2-((3-methoxypyridin-2-yl)amino)cyclopent-2-enone

Compound **1i** was obtained as yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (t, $J = 2.8\text{ Hz}$, 1H), 7.83 (d, $J = 5.2\text{ Hz}$, 1H), 7.37 (br, 1H), 6.95 (d, $J = 7.6\text{ Hz}$, 1H), 6.72 (dd, $J = 7.6, 5.2\text{ Hz}$, 1H), 3.87 (s, 3H), 2.69 (dd, $J = 7.6, 3.2\text{ Hz}$, 2H), 2.45-2.43(m, 2H).

^{13}C NMR (100 MHz, CDCl_3) δ 204.69, 145.44, 142.96, 138.26, 137.90, 133.44, 114.64, 114.18, 55.27, 32.37, 24.57.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}_2$: 205.0972; found 205.0978.

2-((3-methoxypyridin-2-yl)amino)cyclohex-2-enone

Compound **1j** was obtained as yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.03 (t, $J = 4.8$ Hz, 1H), 7.86 (br, 1H), 7.77 (d, $J = 4.8$ Hz, 1H), 6.91 (d, $J = 8.0$ Hz, 1H), 6.66 (dd, $J = 7.6, 5.2$ Hz, 1H), 3.87 (s, 3H), 2.59-2.52 (m, 4H), 2.02 (q, $J = 6.4$ Hz, 2H).

^{13}C NMR (100 MHz, CDCl_3) δ 195.12, 146.48, 143.11, 137.78, 133.80, 123.76, 114.17, 113.91, 55.31, 37.60, 24.87, 22.80.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_2$: 219.1128; found 219.1130.

Characterization of Products in Details

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-phenylcyclopent-2-enone

Petroleum ether/EtOAc =4/1 as eluate and **2a** was obtained as yellow solid (55.3 mg, 94%, condition A; 279.6 mg, 95%, 1mmol scale). ¹H NMR (400 MHz, CDCl₃) δ 7.47-7.47 (m, 2H), 7.36 (d, *J* = 4.0 Hz, 1H), 7.28-7.21 (m, 3H), 6.94-6.91 (m, 2H), 6.56 (dd, *J* = 8.0, 5.2Hz, 1H), 3.88 (s, 3H), 3.33 (dd, *J* = 17.2, 6.8 Hz, 1H), 2.72-2.62 (m, 2H), 1.32 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.65, 149.12, 144.47, 143.65, 137.94, 136.53, 132.90, 128.78, 127.62, 127.55, 114.80, 114.52, 55.22, 37.87, 36.29, 16.42.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₈H₁₉N₂O₂: 295.1441; found 295.1442.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(p-tolyl)cyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2b** was obtained as yellow solid (55.5 mg, 90%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m, 3H), 7.06 (d, *J* = 8.0 Hz, 2H), 6.93 (d, *J* = 7.6 Hz, 1H), 6.84 (br, 1H), 6.57 (dd, *J* = 8.0, 5.2 Hz, 1H), 3.89 (s, 3H), 3.31 (dd, *J* = 17.2, 7.2 Hz, 1H), 2.70-2.61 (m, 2H), 2.32 (s, 3H), 1.31 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.63, 150.38, 144.85, 143.56, 139.17, 138.05, 133.33, 132.49, 128.34, 127.66, 114.73, 114.36, 55.19, 37.74, 36.15, 21.36, 16.40.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₉H₂₁N₂O₂: 309.1598; found 309.1609.

3-(4-methoxyphenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =3/1 as eluate and **2c** was obtained as yellow solid (59.0 mg, 91%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 8.8 Hz, 2H), 7.43-7.42 (m, 1H), 6.92 (d, *J* = 7.6 Hz, 1H), 6.81 (br, 1H), 6.77 (d, *J* = 8.8 Hz, 2H), 6.57 (dd, *J* = 7.6, 5.2 Hz, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 3.31 (dd, *J* = 16.9, 7.2 Hz, 1H), 2.68 – 2.59 (m, 2H), 1.29 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.55, 160.23, 150.71, 145.01, 143.56, 138.12, 131.76, 129.54, 128.66, 114.69, 114.26, 113.01, 55.20, 55.14, 37.63, 36.06, 16.50.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₉H₂₁N₂O₃: 325.1547; found 325.1554.

3-(4-fluorophenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2d** was obtained as yellow solid (55.8 mg, 89%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.46 (dd, *J* = 8.8, 5.6 Hz, 2H), 7.36 (dd, *J* = 4.2, 1.2 Hz, 1H), 6.95-6.89 (m, 4H), 6.58 (dd, *J* = 8.0, 5.2 Hz, 1H), 3.89 (s, 3H), 3.30 (dd, *J* = 17.2, 7.2 Hz, 1H), 2.70-2.61 (m, 2H), 1.31 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.49, 162.71 (d, *J*=248.3 Hz), 147.81, 144.30, 143.68, 137.85, 132.74 (d, *J*=3.3 Hz), 132.56, 129.67 (d, *J* = 8.3 Hz), 114.71 (d, *J* = 24.2 Hz), 114.66, 114.59, 55.20, 37.73, 36.25, 16.40.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₈H₁₈FN₂O₂: 313.1347; found 313.1358.

3-(4-chlorophenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2e** was obtained as yellow solid (59.8 mg, 91%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.35 (m, 3H), 7.19 (d, *J* = 8.4 Hz, 2H), 6.99 (br, 1H), 6.94 (dd, *J* = 8, 0.8 Hz, 1H), 6.58 (dd, *J* = 8.0, 5.2 Hz, 1H), 3.89 (s, 3H), 3.29 (dd, *J* = 17.6, 7.2 Hz, 1H), 2.68-2.61 (m, 2H), 1.31 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.44, 146.82, 144.08, 143.71, 137.87, 135.16, 134.39, 132.92, 129.00, 127.65, 114.89, 114.83, 55.24, 37.78, 36.18, 16.41.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₈H₁₈ClN₂O₂: 329.1051; found 329.1065.

3-(4-bromophenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2f** was obtained as yellow solid (47.0 mg, 63%, condition A; 59.0 mg, 79%, condition B). ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.29 (m, 5H), 6.99 (br, 1H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.59 (dd, *J* = 7.6, 4.8 Hz, 1H), 3.89 (s, 3H), 3.29 (dd, *J* = 17.2, 7.2 Hz, 1H), 2.69-2.61 (m, 2H), 1.31 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.48, 146.82, 144.05, 143.73, 137.89, 135.63, 132.97, 130.62, 129.24, 122.79, 114.93, 114.88, 55.26, 37.80, 36.14, 16.40.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₈H₁₈BrN₂O₂: 373.0546; found 373.0555.

4-(2-((3-methoxypyridin-2-yl)amino)-4-methyl-3-oxocyclopent-1-en-1-yl)benzotrile

Petroleum ether/EtOAc =4/1 as eluate and **2g** was obtained as yellow solid (33.2 mg, 52%, condition A; 58.8 mg, 92%, condition B). ¹H NMR (400 MHz, CDCl₃) δ 7.49p-7.43 (m, 4H), 7.25 d, *J*=5.2 Hz, 1H), 7.18 (br, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 6.60 (dd, *J* = 7.6, 5.2 Hz, 1H), 3.91 (s, 3H), 3.30 (dd, *J* = 17.2, 7.2 Hz, 1H), 2.71-2.65 (m, 2H), 1.33 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 207.28, 143.92, 143.25, 143.12, 141.83, 137.51, 133.92, 131.02, 128.03, 118.92, 115.43, 115.17, 111.13, 55.32, 37.95, 36.13, 16.37. HRMS: *m/z*: [M + H]⁺ calculated for C₁₉H₁₈N₃O₂: 320.1394; found 320.1399.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(4-(trifluoromethyl)phenyl)cyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2h** was obtained as yellow solid (29.0 mg, 40%, condition A; 52.2 mg, 72%, condition B). ¹H NMR (400 MHz, CDCl₃) δ 7.52-7.45 (m, 4H), 7.27 (dd, *J* = 5.2, 1.2 Hz, 1H), 7.09 (br, 1H), 6.95 (dd, *J* = 7.9, 1.2 Hz, 1H), 6.58 (dd, *J* = 8.0, 5.2 Hz, 1H), 3.90 (s, 3H), 3.32 (dd, *J* = 17.2, 7.2 Hz, 1H), 2.75-2.64 (m, 2H), 1.33 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 207.49, 145.03, 143.84, 143.68, 140.56, 137.68, 133.68, 129.87 (q, *J* = 32.1 Hz), 127.77, 124.25 (q, *J* = 3.8 Hz), 124.02 (q, *J* = 270.6 Hz), 115.14, 114.05, 55.28, 37.94, 36.31, 16.38. HRMS: *m/z*: [M + H]⁺ calculated for C₁₉H₁₈F₃N₂O₂: 363.1315; found 363.1318.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(*m*-tolyl)cyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2i** was obtained as yellow solid (56.7 mg, 92%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 4.8 Hz, 1H), 7.29-7.28 (m, 2H), 7.14-7.07 (m, 2H), 6.94 (d, *J* = 7.6 Hz, 1H), 6.88 (br, 1H), 6.57 (dd, *J* = 7.6, 5.2 Hz, 1H), 3.90 (s, 3H), 3.32 (dd, *J* = 17.2, 6.8 Hz, 1H), 2.71-2.61 (m, 2H), 2.24 (s, 3H), 1.32 (d, *J* = 7.4 Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.61, 149.15, 144.54, 143.67, 137.99, 137.00, 136.30, 132.89, 129.55, 128.25, 127.41, 124.91, 114.78, 114.45, 55.22, 37.84, 36.29, 21.26, 16.40.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$: 309.1598; found 309.1613.

3-(3-methoxyphenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =3/1 as eluate and 2j was obtained as faint yellow solid (59.7 mg, 92%, condition A). ^1H NMR (400 MHz, CDCl_3) δ 7.40 (d, $J = 4.8$ Hz, 1H), 7.16 (t, $J = 7.6$ Hz, 1H), 7.09 (d, $J = 7.6$ Hz, 1H), 7.01 (s, 1H), 6.93 (d, $J = 8.0$ Hz, 1H), 6.89 (br, 1H), 6.82 (dd, $J = 8.0, 2.0$ Hz, 1H), 6.58 (dd, $J = 7.6, 4.8$ Hz, 1H), 3.87 (s, 3H), 3.57 (s, 3H), 3.31 (dd, $J = 17.2, 6.8$ Hz, 1H), 2.71-2.62 (m, 2H), 1.31 (d, $J = 7.6$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.64, 158.81, 148.84, 144.47, 143.70, 138.02, 137.68, 133.04, 128.49, 120.19, 115.17, 114.85, 114.62, 112.80, 55.25, 54.89, 37.85, 36.32, 16.38.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_3$: 325.1547; found 325.1549.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(3-nitrophenyl)cyclopent-2-enone

Petroleum ether/EtOAc =3/1 as eluate and 2k was obtained as yellow solid (29.2 mg, 43%, condition B). ^1H NMR (400 MHz, CDCl_3) δ 8.19-8.18 (m, 1H), 8.08 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.67 (d, $J = 7.6$ Hz, 1H), 7.36 (t, $J = 8.0$ Hz, 1H), 7.23-7.21 (m, 2H), 6.96 (dd, $J = 7.6, 0.8$ Hz, 1H), 6.58 (dd, $J = 8.0, 5.2$ Hz, 1H), 3.93 (s, 3H), 3.36 (dd, $J = 17.2, 7.2$ Hz, 1H), 2.77-2.67 (m, 2H), 1.33 (d, $J = 7.6$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.32, 147.42, 144.13, 143.36, 142.59, 138.79, 137.44, 133.78, 133.52, 128.04, 122.68, 122.52, 115.44, 115.30, 55.40, 37.94, 36.18, 16.43.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_4$: 340.1292; found 340.1295.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(o-tolyl)cyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2l** was obtained as yellow solid (20.4 mg, 33%, condition B). ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.30 (m, 1H), 7.19-7.12 (m, 2H), 7.10 (dd, *J* = 5.2, 1.2 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.87 (br, 1H), 6.82 (dd, *J* = 8.0, 0.8 Hz, 1H), 6.47 (dd, *J* = 7.8, 4.8 Hz, 1H), 3.81 (s, 3H), 3.20 (dd, *J* = 17.6, 6.8 Hz, 1H), 2.71-2.58 (m, 2H), 2.06 (s, 3H), 1.33 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 207.14, 148.48, 143.86, 142.99, 138.94, 137.48, 135.30, 134.14, 129.53, 127.56, 126.43, 124.99, 114.69, 114.64, 55.15, 39.02, 38.46, 19.83, 16.50.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₉H₂₁N₂O₂: 309.1598; found 309.1613.

3-(2-methoxyphenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =4/1 as eluate and **2m** was obtained as faint yellow solid (58.4 mg, 90%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.35 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.28-7.23 (m, 2H), 7.08 (br, 1H), 6.91 (td, *J* = 7.6, 0.4 Hz, 1H), 6.84 (dd, *J* = 7.6, 1.2 Hz, 1H), 6.72 (d, *J* = 8.4 Hz, 1H), 6.48 (dd, *J* = 7.6, 4.8 Hz, 1H), 3.83 (s, 3H), 3.54 (s, 3H), 3.28 (dd, *J* = 17.6, 7.2 Hz, 1H), 2.71-2.63 (m, 2H), 1.31 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.07, 156.25, 144.60, 144.29, 142.98, 137.74, 134.35, 129.63, 127.65, 127.45, 119.93, 114.36, 113.96, 110.19, 55.13, 54.62, 38.34, 37.74, 16.14.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₉H₂₁N₂O₃: 325.1547; found 325.1551.

3-(2-fluorophenyl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2n** was obtained as yellow solid (57.5 mg, 92%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.37 (td, *J* = 7.6, 1.6 Hz, 1H), 7.25-7.19(m, 1H), 7.15(dd, *J*=5.2, 1.6 Hz, 1H), 7.13 (br, 1H), 7.03 (td, *J* = 7.6, 0.8 Hz, 1H), 6.88-6.83 (m, 2H), 6.51 (dd, *J* = 7.6, 4.8 Hz, 1H), 3.85 (s, 3H), 3.28 (dd, *J* = 17.2, 6.8 Hz, 1H), 2.73-2.61 (m, 2H), 1.32 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.14, 160.46 (d, *J*=249.0 Hz), 143.93, 143.29, 140.04, 137.35, 134.06, 129.71 (d, *J* = 8.5 Hz), 128.08 (d, *J* = 4.2 Hz), 126.85 (d, *J* = 14.7 Hz), 123.14 (d, *J* = 3.3 Hz), 115.03, 114.92 (d, *J* = 22.1 Hz), 114.74, 114.66, 55.19, 38.10, 37.43, 16.28.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₈H₁₈FN₂O₂: 313.1347; found 313.1357.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(thiophen-2-yl)cyclopent-2-enone

Petroleum ether/EtOAc =4/1 as eluate and **2o** was obtained as yellow solid (57.1 mg, 95%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.45 (dd, *J* = 5.2, 0.8 Hz, 1H), 7.33 (dd, *J*=3.6, 0.8 Hz, 1H), 7.05 (dd, *J* = 5.2, 4.0 Hz, 1H), 6.98 (dd, *J*=8.0, 1.2 Hz, 1H), 6.65 (dd, *J* = 7.6, 4.8 Hz, 1H), 6.51 (br, 1H), 3.90 (s, 3H), 3.39 (dd, *J* = 17.2, 7.6 Hz, 1H), 2.74-2.66 (m, 2H), 1.31 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 206.73, 149.36, 145.80, 143.61, 138.42, 137.71, 131.69, 130.13, 128.78, 126.93, 115.09, 114.64, 55.35, 37.98, 35.74, 16.53.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₆H₁₇N₂O₂S: 301.1005; found 301.1008.

3-(furan-2-yl)-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =6/1 as eluate and **2p** was obtained as brown oil (54.0 mg, 95%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J* = 5.2, 1.6 Hz, 1H), 7.43 (s, 1H), 6.96 (dd, *J* = 8.0, 1.2 Hz, 1H), 6.85 (br, 1H), 6.66 (dd, *J* = 8.0, 5.2 Hz, 1H), 6.44-6.42 (m, 2H), 3.88 (s, 3H), 3.29 (dd, *J* = 17.2, 6.8 Hz, 1H), 2.69-2.57 (m, 2H), 1.29 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 206.20, 150.74, 145.05, 143.85, 143.62, 139.29, 138.19, 130.89, 115.00, 114.81, 114.15, 112.01, 55.23, 37.70, 33.41, 16.39.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₆H₁₇N₂O₃: 285.1234; found 285.1238.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(pyridin-3-yl)cyclopent-2-enone

Petroleum ether/EtOAc =3/1 as eluate and **2q** was obtained as yellow solid (29.5 mg, 50%, condition A; 53.2 mg, 90%, condition B). ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 1.6 Hz, 1H), 8.44 (dd, *J* = 4.8, 1.2 Hz, 1H), 7.66 (dt, *J*=8.0, 2.0 Hz, 1H), 7.28 (dd, *J* = 4.8, 1.2 Hz, 1H), 7.17-7.13 (m, 2H), 6.94 (dd, *J* = 7.6, 1.2 Hz, 1H), 6.58 (dd, *J* = 7.6, 4.8 Hz, 1H), 3.90 (s, 3H), 3.34 (dd, *J* = 16.8, 6.8 Hz, 1H), 2.73-2.64 (m, 2H), 1.33 (d, *J* = 7.2Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.23, 148.89, 148.74, 143.91, 143.61, 143.37, 137.64, 134.58, 133.46, 132.96, 122.34, 115.16, 115.09, 55.29, 37.84, 35.85, 16.42.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₇H₁₈N₃O₂: 296.1394; found 296.1399.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(pyridin-4-yl)cyclopent-2-enone

Petroleum ether/EtOAc =4/1 as eluate and **2r** was obtained as yellow solid (33.1 mg, 56%, condition B). ^1H NMR (400 MHz, CDCl_3) δ 8.45 (d, $J = 6.0$ Hz, 2H), 7.28 (dd, $J = 4.8, 1.2$ Hz, 1H), 7.20 (dd, $J = 4.8, 1.2$ Hz, 2H), 7.15 (br, 1H), 6.96 (dd, $J = 8.0, 0.8$ Hz, 1H), 6.59 (dd, $J = 8.0, 5.2$ Hz, 1H), 3.90 (s, 3H), 3.29 (dd, $J = 17.6, 7.2$ Hz, 1H), 2.71-2.63 (m, 2H), 1.32 (d, $J = 7.6$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.38, 149.01, 144.57, 143.86, 143.27, 142.40, 137.61, 134.40, 121.66, 115.48, 115.21, 55.31, 37.95, 35.84, 16.32.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{18}\text{N}_3\text{O}_2$: 296.1394; found 296.1401.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(naphthalen-2-yl)cyclopent-2-enone

Petroleum ether/EtOAc =6/1 as eluate and **2s** was obtained as yellow solid (57.9 mg, 84%, condition A). ^1H NMR (400 MHz, CDCl_3) δ 7.96 (s, 1H), 7.76 (d, $J = 9.2$ Hz, 2H), 7.61 (s, 2H), 7.48-7.43 (m, 2H), 7.25 (d, $J = 4.8$ Hz, 1H), 7.04 (br, 1H), 6.93 (d, $J = 7.6$ Hz, 1H), 6.52 (dd, $J = 7.6, 5.2$ Hz, 1H), 3.91 (s, 3H), 3.45 (dd, $J = 16.8, 6.8$ Hz, 1H), 2.83 (dd, $J = 17.2, 2.0$ Hz, 1H), 2.75-2.68 (m, 1H), 1.36 (d, $J = 7.2$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.62, 148.59, 144.56, 143.64, 137.99, 134.26, 133.28, 133.15, 132.63, 128.57, 127.44, 126.98, 126.67, 126.60, 126.03, 125.57, 114.84, 114.62, 55.26, 37.91, 36.44, 16.49.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_2$: 345.1598; found 345.1603.

(E)-2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-(prop-1-en-1-yl)cyclopent-2-enone

Petroleum ether/EtOAc =6/1 as eluate and **2t** was obtained as brown oil (43.9 mg, 85%, condition A). ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 5.2$ Hz, 1H), 6.96-6.93 (m, 2H), 6.78 (br, 1H), 6.68 (dd, $J = 7.6, 4.8$ Hz, 1H), 6.19-6.10 (m, 1H), 3.87 (s, 3H), 3.03 (dd, $J = 16.8, 6.8$ Hz, 1H), 2.58-2.50 (m, 1H), 2.34 (dd, $J = 17.2, 2.4$ Hz, 1H), 1.88 (d, $J = 6.8$ Hz, 3H), 1.23 (d, $J = 7.6$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3) δ 207.09, 148.30, 145.63, 143.18, 138.08, 131.76, 131.54, 128.75, 114.84, 114.71, 55.27, 37.60, 33.15, 19.14, 16.69.

HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_2$: 259.1441; found 259.1441.

(E)-2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-styrylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2u** was obtained as yellow solid (55.1 mg, 86%, condition A; 285.1 mg, 89%, 1 mmol scale). ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 16.4 Hz, 1H), 7.79 (d, *J* = 5.2 Hz, 1H), 7.46 (d, *J* = 7.6 Hz, 2H), 7.32 (t, *J* = 7.4 Hz, 2H), 7.27-7.23 (m, 1H), 7.15 (br, 1H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.86 (d, *J* = 16.4 Hz, 1H), 6.76 (dd, *J* = 7.6, 5.2 Hz, 1H), 3.90 (s, 3H), 3.19 (dd, *J* = 16.4, 6.8 Hz, 1H), 2.66-2.58 (m, 1H), 2.49 (dd, *J* = 16.4, 2.0 Hz, 1H), 1.30 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 206.71, 144.95, 144.44, 143.39, 138.01, 137.16, 133.28, 131.53, 128.65, 128.27, 127.12, 126.27, 115.35, 115.11, 55.34, 37.63, 33.06, 16.75.

HRMS: *m/z*: [M + H]⁺ calculated for C₂₀H₂₁N₂O₂: 321.1598; found 321.1607.

2-((3-methoxypyridin-2-yl)amino)-3,5-dimethylcyclopent-2-enone

Petroleum ether/EtOAc =7/1 as eluate and **2v** was obtained as pale oil (44.1 mg, 95%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 4.8 Hz, 1H), 6.93 (d, *J* = 7.6 Hz, 1H), 6.66 (dd, *J* = 8.0, 5.2 Hz, 1H), 6.56 (br, 1H), 3.88 (s, 3H), 2.91 (dd, *J* = 18.0, 6.8 Hz, 1H), 2.55-2.48 (m, 1H), 2.26 (d, *J* = 18.0 Hz, 1H), 2.17 (s, 3H), 1.23 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.43, 156.93, 146.17, 143.09, 138.07, 134.37, 114.64, 114.18, 55.19, 39.30, 38.32, 19.44, 16.34.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₃H₁₇N₂O₂: 233.1285; found 233.1278.

3-ethyl-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =7/1 as eluate and **2w** was obtained as pale oil (44.8 mg, 91%, condition A; 234.0 mg, 95%, 1.0 mmol scale). ¹H NMR (400 MHz, CDCl₃) δ 7.69 (dd, *J* =

5.2, 0.8 Hz, 1H), 6.90 (dd, $J = 8.0, 0.8$ Hz, 1H), 6.64 (dd, $J = 8.0, 5.2$ Hz, 1H), 6.50 (br, 1H), 3.85 (s, 3H), 2.90 (dd, $J = 18.0, 6.8$ Hz, 1H), 2.59 (q, $J = 7.6$ Hz, 2H), 2.52-2.45 (m, 1H), 2.23 (d, $J = 18.0$ Hz, 1H), 1.21 (d, $J = 7.2$ Hz, 3H), 1.13 (t, $J = 7.6$ Hz, 3H).
 ^{13}C NMR (100 MHz, CDCl_3) δ 207.78, 162.27, 146.17, 143.04, 138.04, 133.38, 114.64, 114.18, 55.19, 38.15, 36.16, 25.81, 16.43, 11.08.
HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_2$: 247.1441; found 247.1450.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-tridecylcyclopent-2-enone

Petroleum ether/EtOAc =7/1 as eluate and **2x** was obtained as pale oil (51.0 mg, 64%, condition A; 66.2 mg, 83%, condition B). ^1H NMR (400 MHz, CDCl_3) δ 7.68 (dd, $J = 5.2, 1.2$ Hz, 1H), 6.91 (d, $J = 8.0$ Hz, 1H), 6.64 (dd, $J = 7.6, 4.8$ Hz, 1H), 6.51 (br, 1H), 3.86 (s, 3H), 2.89 (dd, $J = 18.4, 6.8$ Hz, 1H), 2.57 (t, $J = 7.6$ Hz, 2H), 2.52-2.45 (m, 1H), 2.23 (d, $J = 18.0$ Hz, 1H), 1.56-1.51 (m, 2H), 1.24-1.2 (m, 23H), 0.87 (t, $J = 6.8$ Hz, 3H).
 ^{13}C NMR (100 MHz, CDCl_3) δ 207.74, 161.24, 146.17, 143.06, 138.07, 133.76, 114.61, 114.15, 55.19, 38.19, 36.87, 32.76, 31.87, 29.74, 29.64, 29.60(s, 2C), 29.58, 29.47, 29.37, 29.31, 26.80, 22.64, 16.49, 14.07.
HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{25}\text{H}_{41}\text{N}_2\text{O}_2$: 401.3163; found 401.3177.

3-Benzyl-2-((3-methoxypyridin-2-yl)amino)-5-methylcyclopent-2-enone

Petroleum ether/EtOAc =6/1 as eluate and **2y** was obtained as brown oil (51.8 mg, 84%, condition A). ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, $J = 4.8$ Hz, 1H), 7.29-7.25 (m, 2H), 7.22 (m, 3H), 6.94 (d, $J = 7.6$ Hz, 1H), 6.69-6.66 (m, 2H), 4.03 (s, 2H), 3.88 (s, 3H), 2.74 (dd, $J = 18.0, 6.8$ Hz, 1H), 2.48-2.42 (m, 1H), 2.08 (d, $J = 18.0$ Hz, 1H), 1.16 (d, $J = 7.6$ Hz, 3H).
 ^{13}C NMR (100 MHz, CDCl_3) δ 207.84, 157.38, 146.01, 143.23, 138.47, 138.03, 134.05, 129.15, 128.43, 126.29, 114.84, 114.50, 55.29, 39.14, 38.27, 36.58, 16.33.
HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$: 309.1598; found 309.1604.

2-((3-methoxypyridin-2-yl)amino)-5-methyl-3-phenethylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **2z** was obtained as pale oil (48.4 mg, 75%, condition A; 54.8 mg, 85%, condition B). ¹H NMR (400 MHz, CDCl₃) δ 7.75 (dd, *J* = 5.2, 1.6 Hz, 1H), 7.26-7.23 (m, 2H), 7.19-7.13 (m, 3H), 6.93 (dd, *J* = 8.0, 1.2 Hz, 1H), 6.68 (dd, *J* = 8.0, 5.2 Hz, 1H), 6.59 (br, 1H), 3.87 (s, 3H), 2.98-2.86 (m, 5H), 2.54-2.44 (m, 1H), 2.21 (dd, *J* = 18.0, 1.6 Hz, 1H), 1.19 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.58, 158.40, 146.02, 143.08, 141.59, 138.03, 134.04, 128.28, 128.21, 125.89, 114.71, 114.38, 55.19, 38.15, 37.38, 34.72, 32.80, 16.40.

HRMS: *m/z*: [M + H]⁺ calculated for C₂₀H₂₃N₂O₂: 323.1754; found 323.1768.

5-methyl-3-phenyl-2-(pyridin-2-ylamino)cyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **3a** was obtained as yellow solid (21.1 mg, 40%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, *J* = 4.4 Hz, 1H), 7.52-7.49 (m, 2H), 7.30-7.24 (m, 4H), 6.76 (br, 1H), 6.76 (dd, *J* = 5.6, 6.8 Hz, 1H), 6.13 (d, *J* = 8.4 Hz, 1H), 3.31 (dd, *J* = 17.6, 7.2 Hz, 1H), 2.70-2.63 (m, 2H), 1.33 (d, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.28, 153.42, 148.03, 147.11, 136.94, 135.48, 133.39, 129.42, 128.25, 127.63, 115.57, 109.90, 37.82, 36.08, 16.57.

HRMS: *m/z*: [M + H]⁺ calculated for C₁₇H₁₇N₂O: 265.1335; found 265.1340.

5-methyl-2-((3-methylpyridin-2-yl)amino)-3-phenylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **3b** was obtained as yellow solid (10.0 mg, 18%, condition A). ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 3.6 Hz, 1H), 7.40-7.38 (m, 2H), 7.32 (dd, *J* = 7.2, 1.8 Hz, 1H), 7.24-7.18 (m, 3H), 6.57 (dd, *J* = 7.2, 5.2 Hz, 1H), 6.27 (br, 1H), 3.35 (dd, *J* = 17.6, 7.6 Hz, 1H), 2.73-2.65 (m, 2H), 2.30 (s, 3H), 1.34 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 207.73, 151.99, 147.48, 144.93, 137.66, 136.61, 133.51, 128.70, 127.59, 127.50, 119.99, 115.76, 37.90, 36.31, 17.34, 16.47.

HRMS: m/z : $[M + H]^+$ calculated for $C_{18}H_{19}N_2O$: 279.1492; found 279.1495.

2-((3-(benzyloxy)pyridin-2-yl)amino)-5-methyl-3-phenylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **3d** was obtained as yellow oil (42.2 mg, 57%, condition A). 1H NMR (400 MHz, $CDCl_3$) δ 7.48 (dd, $J = 7.2, 5.2$ Hz, 4H), 7.43-7.36 (m, 4H), 7.27-7.22 (m, 3H), 7.00 (d, $J = 7.2$ Hz, 1H), 6.96 (br, 1H), 6.55 (dd, $J = 8.0, 5.2$ Hz, 1H), 5.14 (s, 2H), 3.33 (dd, $J = 17.6, 7.2$ Hz, 1H), 2.72-2.62 (m, 2H), 1.32 (d, $J = 7.6$ Hz, 3H).

^{13}C NMR (100 MHz, $CDCl_3$) δ 207.62, 149.42, 144.93, 142.76, 138.46, 136.47, 136.06, 133.06, 128.85, 128.71, 128.28, 127.63, 127.54, 116.71, 114.52, 70.37, 37.92, 36.29, 16.41.

HRMS: m/z : $[M + H]^+$ calculated for $C_{24}H_{23}N_2O_2$: 371.1754; found 371.1755.

2-((3,5-dimethoxypyridin-2-yl)amino)-5-methyl-3-phenylcyclopent-2-enone

Petroleum ether/EtOAc =3/1 as eluate and **3e** was obtained as yellow solid (48.7 mg, 75%, condition A). 1H NMR (400 MHz, $CDCl_3$) δ 7.46-7.44 (m, 2H), 7.25-7.22 (m, 3H), 7.03 (d, $J = 2.4$ Hz, 1H), 6.72 (br, 1H), 6.65 (d, $J = 2.4$ Hz, 1H), 3.87 (s, 3H), 3.68 (s, 3H), 3.31 (dd, $J = 17.2, 7.2$ Hz, 1H), 2.71-2.61 (m, 2H), 1.31 (d, $J = 7.2$ Hz, 3H).

^{13}C NMR (100MHz, $CDCl_3$) δ 207.80, 150.29, 147.29, 144.41, 138.74, 136.63, 133.21, 128.57, 127.63, 127.51, 120.74, 105.92, 56.12, 55.41, 37.84, 36.21, 16.45.

HRMS: m/z : $[M + H]^+$ calculated for $C_{19}H_{21}N_2O_3$: 325.1547; found 325.1547.

2-((5-methoxypyridin-2-yl)amino)-5-methyl-3-phenylcyclopent-2-enone

Petroleum ether/EtOAc =4/1 as eluate and **3f** was obtained as yellow solid (8.8 mg, 15%, condition A). 1H NMR (400 MHz, $CDCl_3$) δ 7.80 (d, $J = 2.8$ Hz, 1H), 7.47-7.44 (m, 2H),

7.28-7.27 (m, 3H), 6.87 (dd, $J = 8.8, 2.8$ Hz, 1H), 6.64 (br, 1H), 6.10 (d, $J = 8.8$ Hz, 1H), 3.72 (s, 3H), 3.28 (dd, $J = 17.2, 7.2$ Hz, 1H), 2.68-2.62 (m, 2H), 1.33 (d, $J = 7.6$ Hz, 3H).
 ^{13}C NMR (100 MHz, CDCl_3) δ 207.42, 150.33, 147.44, 144.59, 135.68, 133.88, 133.84, 129.10, 128.14, 127.59, 123.62, 110.71, 56.05, 37.79, 36.04, 16.60.
HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$: 295.1441; found 295.1447.

2-((3-methoxypyridin-2-yl)amino)-3-phenylcyclopent-2-enone

Petroleum ether/EtOAc =5/1 as eluate and **3i** was obtained as yellow solid (54.4 mg, 97%, condition A). ^1H NMR (400 MHz, CDCl_3) δ 7.49 (d, $J = 6.8$ Hz, 2H), 7.35 (d, $J = 4.8$ Hz, 1H), 7.24-7.23 (m, 3H), 6.93-6.90 (m, 2H), 6.56 (dd, $J = 7.6, 5.2$ Hz, 1H), 3.87 (s, 3H), 3.08 (t, $J=4.4$ Hz, 2H), 2.62 (t, $J=4.4$ Hz, 2H).
 ^{13}C NMR (100 MHz, CDCl_3) δ 204.94, 151.08, 144.39, 143.59, 137.87, 136.42, 134.04, 128.82, 127.55, 127.46, 114.79, 114.53, 55.16, 32.36, 26.96.
HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_2$: 281.1285; found 281.1286.

2-((3-methoxypyridin-2-yl)amino)-[1,1'-biphenyl]-3-ol


Petroleum ether/EtOAc =5/1 as eluate and **3j** was obtained as pale oil (21.6 mg, 37%, condition B). ^1H NMR (400 MHz, CDCl_3) δ 8.12-8.10 (m, 3H), 7.82 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.66 (dd, $J = 7.2, 0.8$ Hz, 1H), 7.53-7.49 (m, 2H), 7.44 (t, $J=7.6$ Hz, 1H), 7.39-7.35 (m, 1H), 6.79-6.75 (m, 1H), 6.66 (d, $J = 7.2$ Hz, 1H), 4.05 (s, 3H).
 ^{13}C NMR (100 MHz, CDCl_3) δ 149.19, 143.38, 141.85, 138.40, 133.21, 130.03, 129.41, 128.43, 127.29, 124.67, 121.55, 117.65, 110.29, 109.45, 103.95, 55.94.
HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_2$: 293.1285; found 293.1287.

2-hydroxy-5-methyl-3-phenylcyclopent-2-enone



Petroleum ether/EtOAc =15/1 as eluate and **4a** was obtained as white solid (24.5 mg, 65%). ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J = 7.2$ Hz, 2H), 7.47-7.43 (m, 2H), 7.38 (t, $J = 7.6$ Hz, 1H), 6.20 (br, 1H), 3.16 (dd, $J = 16.8, 6.4$ Hz, 1H), 2.65-2.57 (m, 1H), 2.47 (dd, $J = 16.8, 1.6$ Hz, 1H), 1.30 (d, $J = 7.2$ Hz, 3H).



^{13}C NMR (100 MHz, CDCl_3) δ 205.66, 146.92, 136.43, 133.82, 129.43, 128.61, 127.77, 36.61, 32.71, 16.62.



HRMS: m/z : $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{12}\text{H}_{13}\text{O}_2$: 189.0910; found 189.0913.






Petroleum ether/EtOAc =15/1 as eluate and **4w**^[9] was obtained as pale oil (21.0 mg, 75%). **4w**₁:**4w**₂=0.57:1. ^1H NMR (400 MHz, CDCl_3) δ **4w**₁) 6.09 (br, 1H), 2.69 (dd, $J = 17.6, 6.4$ Hz, 1H), 2.46-2.38 (m, 3H), 2.07-2.04 (m, 1H), 1.18 (d, $J = 7.2$ Hz, 3H), 1.13 (t, $J = 7.6$ Hz, 3H); **4w**₂) 6.12 (br, 1H), 2.59 (dd, $J = 17.6, 6.0$ Hz, 1H), 2.35-2.30 (m, 1H), 2.12-2.07 (m, 1H), 2.00 (s, 3H), 1.86-1.76 (m, 1H), 1.46-1.35 (m, 1H), 0.93 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ **4w**₁) 206.22, 148.06, 146.93, 37.34, 33.98, 21.59, 16.43, 11.23; **4w**₂) 205.25, 148.30, 143.34, 44.17, 33.95, 24.33, 14.22, 11.13.



























































































































































Reference

- [1] J. J. Kaminski, J. M. Hilbert, B. N. Pramanik, D. M. Solomon, D. J. Conn, R. K. Rizvi, A. J. Elliott, H. Guzik, R. G. Lovey, *J. Med. Chem.* **1987**, *30*, 2031-2046.
- [2] C. Ramesh, B. R. Raju, V. Kavala, C.-W. Kuo, C.-F. Yao, *Tetrahedron* **2011**, *67*, 1187-1192.
- [3] W. Sun, Y. Cui, H. Liu, H. Zhao, W. Zhang, *J. Mol. Struct.* **2012**, *1026*, 133-139.
- [4] L. Testaferri, M. Tiecco, M. Tingoli, D. Bartoli, A. Massoli, *Tetrahedron* **1985**, *41*, 1373-1384.
- [5] M. Liljenberg, T. Brinck, B. Herschend, T. Rein, G. Rockwell, M. Svensson, *J. Org. Chem.* **2010**, *75*, 4696-4705.
- [6] G. T. Bourne, D. J. Kuster, G. R. Marshall, *Chem.-Eur. J.* **2010**, *16*, 8439-8445.
- [7] T. R. Kelly, F. Lang, *Tetrahedron Lett.* **1995**, *36*, 5319-5322.
- [8] A. M. Thompson, A. Blaser, R. F. Anderson, S. S. Shinde, S. G. Franzblau, Z. Ma, W. A. Denny, B. D. Palmer, *J. Med. Chem.* **2009**, *52*, 637-645.
- [9] Z. Wang, B. J. Reinus, G. Dong, *J. Am. Chem. Soc.* **2012**, *134*, 13954-13957.